170 related articles for article (PubMed ID: 33023358)
1. Making a case for using γδ T cells against SARS-CoV-2.
Yazdanifar M; Mashkour N; Bertaina A
Crit Rev Microbiol; 2020 Nov; 46(6):689-702. PubMed ID: 33023358
[TBL] [Abstract][Full Text] [Related]
2. The phenotypic changes of γδ T cells in COVID-19 patients.
Lei L; Qian H; Yang X; Zhang X; Zhang D; Dai T; Guo R; Shi L; Cheng Y; Zhang B; Zhou X; Hu J; Guo Y
J Cell Mol Med; 2020 Oct; 24(19):11603-11606. PubMed ID: 32864865
[TBL] [Abstract][Full Text] [Related]
3. Host Immune Response Driving SARS-CoV-2 Evolution.
Wang R; Hozumi Y; Zheng YH; Yin C; Wei GW
Viruses; 2020 Sep; 12(10):. PubMed ID: 32992592
[TBL] [Abstract][Full Text] [Related]
4. Early Insights into Immune Responses during COVID-19.
St John AL; Rathore APS
J Immunol; 2020 Aug; 205(3):555-564. PubMed ID: 32513850
[TBL] [Abstract][Full Text] [Related]
5. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.
Deng W; Bao L; Liu J; Xiao C; Liu J; Xue J; Lv Q; Qi F; Gao H; Yu P; Xu Y; Qu Y; Li F; Xiang Z; Yu H; Gong S; Liu M; Wang G; Wang S; Song Z; Liu Y; Zhao W; Han Y; Zhao L; Liu X; Wei Q; Qin C
Science; 2020 Aug; 369(6505):818-823. PubMed ID: 32616673
[TBL] [Abstract][Full Text] [Related]
6. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.
Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren HG; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
J Immunol; 2020 Nov; 205(9):2437-2446. PubMed ID: 32878912
[TBL] [Abstract][Full Text] [Related]
7. COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies.
Bergmann CC; Silverman RH
Cleve Clin J Med; 2020 Jun; 87(6):321-327. PubMed ID: 32366502
[No Abstract] [Full Text] [Related]
8. Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome.
Ye C; Chiem K; Park JG; Oladunni F; Platt RN; Anderson T; Almazan F; de la Torre JC; Martinez-Sobrido L
mBio; 2020 Sep; 11(5):. PubMed ID: 32978313
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
10. Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation.
Yang D; Chu H; Hou Y; Chai Y; Shuai H; Lee AC; Zhang X; Wang Y; Hu B; Huang X; Yuen TT; Cai JP; Zhou J; Yuan S; Zhang AJ; Chan JF; Yuen KY
J Infect Dis; 2020 Aug; 222(5):734-745. PubMed ID: 32563187
[TBL] [Abstract][Full Text] [Related]
11. Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).
Chang FY; Chen HC; Chen PJ; Ho MS; Hsieh SL; Lin JC; Liu FT; Sytwu HK
J Biomed Sci; 2020 Jun; 27(1):72. PubMed ID: 32498686
[TBL] [Abstract][Full Text] [Related]
12. Role of neutrophil chemoattractant CXCL5 in SARS-CoV-2 infection-induced lung inflammatory innate immune response in an
Liang Y; Li H; Li J; Yang ZN; Li JL; Zheng HW; Chen YL; Shi HJ; Guo L; Liu LD
Zool Res; 2020 Nov; 41(6):621-631. PubMed ID: 33045777
[TBL] [Abstract][Full Text] [Related]
13. Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2).
Sarkar B; Ullah MA; Johora FT; Taniya MA; Araf Y
Immunobiology; 2020 May; 225(3):151955. PubMed ID: 32517882
[TBL] [Abstract][Full Text] [Related]
14. HIV and SARS-CoV-2: points to consider to face this new pandemic.
Prieto Pozo AA; Salvador Sagüez FLD
Medwave; 2020 Oct; 20(9):e8049. PubMed ID: 33141814
[TBL] [Abstract][Full Text] [Related]
15. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
16. Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines.
Moise L; Ross TM; Hoft DF; Martin WD; De Groot AS
Expert Rev Vaccines; 2020 Sep; 19(9):781-784. PubMed ID: 32962468
[No Abstract] [Full Text] [Related]
17. Molecular profiling of immune cell-enriched Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) interacting protein USP13.
Biterge Süt B
Life Sci; 2020 Oct; 258():118170. PubMed ID: 32735883
[TBL] [Abstract][Full Text] [Related]
18. Activation and evasion of type I interferon responses by SARS-CoV-2.
Lei X; Dong X; Ma R; Wang W; Xiao X; Tian Z; Wang C; Wang Y; Li L; Ren L; Guo F; Zhao Z; Zhou Z; Xiang Z; Wang J
Nat Commun; 2020 Jul; 11(1):3810. PubMed ID: 32733001
[TBL] [Abstract][Full Text] [Related]
19. More bricks in the wall against SARS-CoV-2 infection: involvement of γ9δ2 T cells.
Rijkers G; Vervenne T; van der Pol P
Cell Mol Immunol; 2020 Jul; 17(7):771-772. PubMed ID: 32467616
[No Abstract] [Full Text] [Related]
20. GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.
Rudd CE
Front Immunol; 2020; 11():1638. PubMed ID: 32695123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
